76 results
424B5
IKT
Inhibikase Therapeutics Inc
22 May 24
Prospectus supplement for primary offering
8:55am
of a majority of the voting power of the shares present in person or represented by proxy at such meeting and entitled to vote on the subject matter … shall be the act of the stockholders, except as otherwise required by law. The holders of a majority of the stock issued and outstanding and entitled
8-K
EX-4.4
IKT
Inhibikase Therapeutics Inc
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable … of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest.
Section 2. Exercise
8-K
EX-10.3
IKT
Inhibikase Therapeutics Inc
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non … by a majority of the non-employee members of the Board of Directors, provided that such securities are issued as “restricted securities” (as defined
8-K
EX-4.3
IKT
Inhibikase Therapeutics Inc
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable … of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest.
Section 2. Exercise
8-K
EX-4.2
IKT
Inhibikase Therapeutics Inc
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable … of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest.
Section 2. Exercise
8-K
EX-4.1
9o4j7yikhiagp1oyzg1w
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
8-K
EX-4.5
0860ec0h5reeibn
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
8-K
EX-10.1
wubc4
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am